Agilent Technologies, Inc.
Agilent Technologies, Inc. A Peers
See (A) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Diagnostics & Research Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| A | $115.55 | +0.03% | 32.8B | 28.46 | $4.06 | +0.84% |
| DHR-PB | $1,261.26 | -0.78% | 916.8B | 146.01 | $8.64 | +0.58% |
| TMO | $397.89 | +1.36% | 150.2B | 23.35 | $17.04 | +0.41% |
| DHR | $196.40 | +1.01% | 140.6B | 38.06 | $5.16 | +0.58% |
| IDXX | $523.55 | +0.71% | 42.1B | 48.39 | $10.82 | N/A |
| IQV | $154.72 | +0.07% | 26.8B | 21.11 | $7.33 | N/A |
| MTD | $1,154.12 | +0.76% | 24B | 28.79 | $40.09 | N/A |
| NTRA | $171.86 | +0.51% | 23.5B | -116.91 | -$1.47 | N/A |
| WAT | $342.65 | +0.97% | 20.4B | 31.09 | $11.02 | N/A |
| DGX | $179.43 | -0.19% | 20B | 22.68 | $7.91 | +1.70% |
Stock Comparison
A vs DHR-PB Comparison
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 32.8B. In comparison, DHR-PB has a market cap of 916.8B. Regarding current trading prices, A is priced at $115.55, while DHR-PB trades at $1,261.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 28.46, whereas DHR-PB's P/E ratio is 146.01. In terms of profitability, A's ROE is +0.19%, compared to DHR-PB's ROE of +0.07%. Regarding short-term risk, A is more volatile compared to DHR-PB. This indicates potentially higher risk in terms of short-term price fluctuations for A.
A vs TMO Comparison
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 32.8B. In comparison, TMO has a market cap of 150.2B. Regarding current trading prices, A is priced at $115.55, while TMO trades at $397.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 28.46, whereas TMO's P/E ratio is 23.35. In terms of profitability, A's ROE is +0.19%, compared to TMO's ROE of +0.13%. Regarding short-term risk, A is less volatile compared to TMO. This indicates potentially lower risk in terms of short-term price fluctuations for A.
A vs DHR Comparison
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 32.8B. In comparison, DHR has a market cap of 140.6B. Regarding current trading prices, A is priced at $115.55, while DHR trades at $196.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 28.46, whereas DHR's P/E ratio is 38.06. In terms of profitability, A's ROE is +0.19%, compared to DHR's ROE of +0.07%. Regarding short-term risk, A is more volatile compared to DHR. This indicates potentially higher risk in terms of short-term price fluctuations for A.
A vs IDXX Comparison
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 32.8B. In comparison, IDXX has a market cap of 42.1B. Regarding current trading prices, A is priced at $115.55, while IDXX trades at $523.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 28.46, whereas IDXX's P/E ratio is 48.39. In terms of profitability, A's ROE is +0.19%, compared to IDXX's ROE of +0.57%. Regarding short-term risk, A is more volatile compared to IDXX. This indicates potentially higher risk in terms of short-term price fluctuations for A.
A vs IQV Comparison
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 32.8B. In comparison, IQV has a market cap of 26.8B. Regarding current trading prices, A is priced at $115.55, while IQV trades at $154.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 28.46, whereas IQV's P/E ratio is 21.11. In terms of profitability, A's ROE is +0.19%, compared to IQV's ROE of +0.21%. Regarding short-term risk, A is less volatile compared to IQV. This indicates potentially lower risk in terms of short-term price fluctuations for A.
A vs MTD Comparison
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 32.8B. In comparison, MTD has a market cap of 24B. Regarding current trading prices, A is priced at $115.55, while MTD trades at $1,154.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 28.46, whereas MTD's P/E ratio is 28.79. In terms of profitability, A's ROE is +0.19%, compared to MTD's ROE of +1.21%. Regarding short-term risk, A is more volatile compared to MTD. This indicates potentially higher risk in terms of short-term price fluctuations for A.
A vs NTRA Comparison
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 32.8B. In comparison, NTRA has a market cap of 23.5B. Regarding current trading prices, A is priced at $115.55, while NTRA trades at $171.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 28.46, whereas NTRA's P/E ratio is -116.91. In terms of profitability, A's ROE is +0.19%, compared to NTRA's ROE of -0.18%. Regarding short-term risk, A is less volatile compared to NTRA. This indicates potentially lower risk in terms of short-term price fluctuations for A.
A vs WAT Comparison
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 32.8B. In comparison, WAT has a market cap of 20.4B. Regarding current trading prices, A is priced at $115.55, while WAT trades at $342.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 28.46, whereas WAT's P/E ratio is 31.09. In terms of profitability, A's ROE is +0.19%, compared to WAT's ROE of +0.39%. Regarding short-term risk, A is more volatile compared to WAT. This indicates potentially higher risk in terms of short-term price fluctuations for A.
A vs DGX Comparison
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 32.8B. In comparison, DGX has a market cap of 20B. Regarding current trading prices, A is priced at $115.55, while DGX trades at $179.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 28.46, whereas DGX's P/E ratio is 22.68. In terms of profitability, A's ROE is +0.19%, compared to DGX's ROE of +0.13%. Regarding short-term risk, A is more volatile compared to DGX. This indicates potentially higher risk in terms of short-term price fluctuations for A.
A vs PKI Comparison
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 32.8B. In comparison, PKI has a market cap of 14.5B. Regarding current trading prices, A is priced at $115.55, while PKI trades at $115.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 28.46, whereas PKI's P/E ratio is 41.45. In terms of profitability, A's ROE is +0.19%, compared to PKI's ROE of +0.04%. Regarding short-term risk, A is less volatile compared to PKI. This indicates potentially lower risk in terms of short-term price fluctuations for A.
A vs ILMN Comparison
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 32.8B. In comparison, ILMN has a market cap of 14.3B. Regarding current trading prices, A is priced at $115.55, while ILMN trades at $90.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 28.46, whereas ILMN's P/E ratio is -14.88. In terms of profitability, A's ROE is +0.19%, compared to ILMN's ROE of -0.46%. Regarding short-term risk, A is less volatile compared to ILMN. This indicates potentially lower risk in terms of short-term price fluctuations for A.
A vs ICLR Comparison
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 32.8B. In comparison, ICLR has a market cap of 11.8B. Regarding current trading prices, A is priced at $115.55, while ICLR trades at $146.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 28.46, whereas ICLR's P/E ratio is 15.97. In terms of profitability, A's ROE is +0.19%, compared to ICLR's ROE of +0.08%. Regarding short-term risk, A is less volatile compared to ICLR. This indicates potentially lower risk in terms of short-term price fluctuations for A.
A vs TEM Comparison
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 32.8B. In comparison, TEM has a market cap of 11.5B. Regarding current trading prices, A is priced at $115.55, while TEM trades at $68.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 28.46, whereas TEM's P/E ratio is -13.24. In terms of profitability, A's ROE is +0.19%, compared to TEM's ROE of -5.31%. Regarding short-term risk, A is less volatile compared to TEM. This indicates potentially lower risk in terms of short-term price fluctuations for A.
A vs RVTY Comparison
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 32.8B. In comparison, RVTY has a market cap of 11.2B. Regarding current trading prices, A is priced at $115.55, while RVTY trades at $95.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 28.46, whereas RVTY's P/E ratio is 39.26. In terms of profitability, A's ROE is +0.19%, compared to RVTY's ROE of +0.04%. Regarding short-term risk, A is more volatile compared to RVTY. This indicates potentially higher risk in terms of short-term price fluctuations for A.
A vs QGEN Comparison
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 32.8B. In comparison, QGEN has a market cap of 10.1B. Regarding current trading prices, A is priced at $115.55, while QGEN trades at $46.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 28.46, whereas QGEN's P/E ratio is 108.74. In terms of profitability, A's ROE is +0.19%, compared to QGEN's ROE of +0.03%. Regarding short-term risk, A is more volatile compared to QGEN. This indicates potentially higher risk in terms of short-term price fluctuations for A.
A vs EXAS Comparison
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 32.8B. In comparison, EXAS has a market cap of 10B. Regarding current trading prices, A is priced at $115.55, while EXAS trades at $53.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 28.46, whereas EXAS's P/E ratio is -9.59. In terms of profitability, A's ROE is +0.19%, compared to EXAS's ROE of -0.36%. Regarding short-term risk, A is less volatile compared to EXAS. This indicates potentially lower risk in terms of short-term price fluctuations for A.
A vs MEDP Comparison
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 32.8B. In comparison, MEDP has a market cap of 8.9B. Regarding current trading prices, A is priced at $115.55, while MEDP trades at $309.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 28.46, whereas MEDP's P/E ratio is 23.63. In terms of profitability, A's ROE is +0.19%, compared to MEDP's ROE of +0.54%. Regarding short-term risk, A is less volatile compared to MEDP. This indicates potentially lower risk in terms of short-term price fluctuations for A.
A vs CRL Comparison
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 32.8B. In comparison, CRL has a market cap of 7.2B. Regarding current trading prices, A is priced at $115.55, while CRL trades at $147.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 28.46, whereas CRL's P/E ratio is -241.64. In terms of profitability, A's ROE is +0.19%, compared to CRL's ROE of -0.01%. Regarding short-term risk, A is less volatile compared to CRL. This indicates potentially lower risk in terms of short-term price fluctuations for A.
A vs GH Comparison
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 32.8B. In comparison, GH has a market cap of 6.1B. Regarding current trading prices, A is priced at $115.55, while GH trades at $49.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 28.46, whereas GH's P/E ratio is -14.50. In terms of profitability, A's ROE is +0.19%, compared to GH's ROE of +3.69%. Regarding short-term risk, A is less volatile compared to GH. This indicates potentially lower risk in terms of short-term price fluctuations for A.
A vs SYNH Comparison
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 32.8B. In comparison, SYNH has a market cap of 4.5B. Regarding current trading prices, A is priced at $115.55, while SYNH trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 28.46, whereas SYNH's P/E ratio is 61.40. In terms of profitability, A's ROE is +0.19%, compared to SYNH's ROE of +0.08%. Regarding short-term risk, A is more volatile compared to SYNH. This indicates potentially higher risk in terms of short-term price fluctuations for A.
A vs RDNT Comparison
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 32.8B. In comparison, RDNT has a market cap of 4.1B. Regarding current trading prices, A is priced at $115.55, while RDNT trades at $55.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 28.46, whereas RDNT's P/E ratio is -128.44. In terms of profitability, A's ROE is +0.19%, compared to RDNT's ROE of +0.03%. Regarding short-term risk, A is less volatile compared to RDNT. This indicates potentially lower risk in terms of short-term price fluctuations for A.
A vs OLK Comparison
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 32.8B. In comparison, OLK has a market cap of 3.2B. Regarding current trading prices, A is priced at $115.55, while OLK trades at $26.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 28.46, whereas OLK's P/E ratio is -96.59. In terms of profitability, A's ROE is +0.19%, compared to OLK's ROE of -0.05%. Regarding short-term risk, A is more volatile compared to OLK. This indicates potentially higher risk in terms of short-term price fluctuations for A.
A vs SHC Comparison
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 32.8B. In comparison, SHC has a market cap of 3.2B. Regarding current trading prices, A is priced at $115.55, while SHC trades at $11.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 28.46, whereas SHC's P/E ratio is 126.56. In terms of profitability, A's ROE is +0.19%, compared to SHC's ROE of +0.06%. Regarding short-term risk, A is less volatile compared to SHC. This indicates potentially lower risk in terms of short-term price fluctuations for A.
A vs TWST Comparison
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 32.8B. In comparison, TWST has a market cap of 2.1B. Regarding current trading prices, A is priced at $115.55, while TWST trades at $34.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 28.46, whereas TWST's P/E ratio is -10.66. In terms of profitability, A's ROE is +0.19%, compared to TWST's ROE of -0.41%. Regarding short-term risk, A is less volatile compared to TWST. This indicates potentially lower risk in terms of short-term price fluctuations for A.
A vs GRAL Comparison
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 32.8B. In comparison, GRAL has a market cap of 1.6B. Regarding current trading prices, A is priced at $115.55, while GRAL trades at $45.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 28.46, whereas GRAL's P/E ratio is -0.77. In terms of profitability, A's ROE is +0.19%, compared to GRAL's ROE of -0.75%. Regarding short-term risk, A is less volatile compared to GRAL. This indicates potentially lower risk in terms of short-term price fluctuations for A.
A vs VIVO Comparison
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 32.8B. In comparison, VIVO has a market cap of 1.5B. Regarding current trading prices, A is priced at $115.55, while VIVO trades at $33.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 28.46, whereas VIVO's P/E ratio is 21.09. In terms of profitability, A's ROE is +0.19%, compared to VIVO's ROE of +0.12%. Regarding short-term risk, A is more volatile compared to VIVO. This indicates potentially higher risk in terms of short-term price fluctuations for A.
A vs NEOG Comparison
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 32.8B. In comparison, NEOG has a market cap of 1.1B. Regarding current trading prices, A is priced at $115.55, while NEOG trades at $4.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 28.46, whereas NEOG's P/E ratio is -2.22. In terms of profitability, A's ROE is +0.19%, compared to NEOG's ROE of -0.17%. Regarding short-term risk, A is less volatile compared to NEOG. This indicates potentially lower risk in terms of short-term price fluctuations for A.
A vs CDNA Comparison
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 32.8B. In comparison, CDNA has a market cap of 1.1B. Regarding current trading prices, A is priced at $115.55, while CDNA trades at $19.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 28.46, whereas CDNA's P/E ratio is 17.00. In terms of profitability, A's ROE is +0.19%, compared to CDNA's ROE of +0.18%. Regarding short-term risk, A is less volatile compared to CDNA. This indicates potentially lower risk in terms of short-term price fluctuations for A.
A vs OPK Comparison
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 32.8B. In comparison, OPK has a market cap of 1B. Regarding current trading prices, A is priced at $115.55, while OPK trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 28.46, whereas OPK's P/E ratio is -21.50. In terms of profitability, A's ROE is +0.19%, compared to OPK's ROE of -0.03%. Regarding short-term risk, A is less volatile compared to OPK. This indicates potentially lower risk in terms of short-term price fluctuations for A.
A vs FLGT Comparison
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 32.8B. In comparison, FLGT has a market cap of 594.6M. Regarding current trading prices, A is priced at $115.55, while FLGT trades at $19.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 28.46, whereas FLGT's P/E ratio is -14.68. In terms of profitability, A's ROE is +0.19%, compared to FLGT's ROE of -0.04%. Regarding short-term risk, A is less volatile compared to FLGT. This indicates potentially lower risk in terms of short-term price fluctuations for A.
A vs GRALV Comparison
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 32.8B. In comparison, GRALV has a market cap of 579.4M. Regarding current trading prices, A is priced at $115.55, while GRALV trades at $18.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 28.46, whereas GRALV's P/E ratio is N/A. In terms of profitability, A's ROE is +0.19%, compared to GRALV's ROE of N/A. Regarding short-term risk, A is less volatile compared to GRALV. This indicates potentially lower risk in terms of short-term price fluctuations for A.
A vs PSNL Comparison
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 32.8B. In comparison, PSNL has a market cap of 567M. Regarding current trading prices, A is priced at $115.55, while PSNL trades at $6.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 28.46, whereas PSNL's P/E ratio is -4.98. In terms of profitability, A's ROE is +0.19%, compared to PSNL's ROE of -0.49%. Regarding short-term risk, A is less volatile compared to PSNL. This indicates potentially lower risk in terms of short-term price fluctuations for A.
A vs CSTL Comparison
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 32.8B. In comparison, CSTL has a market cap of 534.7M. Regarding current trading prices, A is priced at $115.55, while CSTL trades at $18.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 28.46, whereas CSTL's P/E ratio is -97.47. In terms of profitability, A's ROE is +0.19%, compared to CSTL's ROE of -0.01%. Regarding short-term risk, A is less volatile compared to CSTL. This indicates potentially lower risk in terms of short-term price fluctuations for A.
A vs MYGN Comparison
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 32.8B. In comparison, MYGN has a market cap of 453.5M. Regarding current trading prices, A is priced at $115.55, while MYGN trades at $4.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 28.46, whereas MYGN's P/E ratio is -4.39. In terms of profitability, A's ROE is +0.19%, compared to MYGN's ROE of -0.15%. Regarding short-term risk, A is less volatile compared to MYGN. This indicates potentially lower risk in terms of short-term price fluctuations for A.
A vs CO Comparison
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 32.8B. In comparison, CO has a market cap of 400.1M. Regarding current trading prices, A is priced at $115.55, while CO trades at $2.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 28.46, whereas CO's P/E ratio is 5.06. In terms of profitability, A's ROE is +0.19%, compared to CO's ROE of +0.11%. Regarding short-term risk, A is less volatile compared to CO. This indicates potentially lower risk in terms of short-term price fluctuations for A.
A vs LAB Comparison
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 32.8B. In comparison, LAB has a market cap of 395M. Regarding current trading prices, A is priced at $115.55, while LAB trades at $1.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 28.46, whereas LAB's P/E ratio is -3.25. In terms of profitability, A's ROE is +0.19%, compared to LAB's ROE of -0.28%. Regarding short-term risk, A is less volatile compared to LAB. This indicates potentially lower risk in terms of short-term price fluctuations for A.
A vs FLDM Comparison
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 32.8B. In comparison, FLDM has a market cap of 294.2M. Regarding current trading prices, A is priced at $115.55, while FLDM trades at $3.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 28.46, whereas FLDM's P/E ratio is -4.74. In terms of profitability, A's ROE is +0.19%, compared to FLDM's ROE of -0.28%. Regarding short-term risk, A is less volatile compared to FLDM. This indicates potentially lower risk in terms of short-term price fluctuations for A.
A vs STIM Comparison
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 32.8B. In comparison, STIM has a market cap of 227.7M. Regarding current trading prices, A is priced at $115.55, while STIM trades at $3.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 28.46, whereas STIM's P/E ratio is -2.62. In terms of profitability, A's ROE is +0.19%, compared to STIM's ROE of -2.09%. Regarding short-term risk, A is less volatile compared to STIM. This indicates potentially lower risk in terms of short-term price fluctuations for A.
A vs PRENW Comparison
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 32.8B. In comparison, PRENW has a market cap of 186.4M. Regarding current trading prices, A is priced at $115.55, while PRENW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 28.46, whereas PRENW's P/E ratio is N/A. In terms of profitability, A's ROE is +0.19%, compared to PRENW's ROE of -0.25%. Regarding short-term risk, A is less volatile compared to PRENW. This indicates potentially lower risk in terms of short-term price fluctuations for A.
A vs NEO Comparison
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 32.8B. In comparison, NEO has a market cap of 180.2M. Regarding current trading prices, A is priced at $115.55, while NEO trades at $7.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 28.46, whereas NEO's P/E ratio is -11.48. In terms of profitability, A's ROE is +0.19%, compared to NEO's ROE of -0.09%. Regarding short-term risk, A is less volatile compared to NEO. This indicates potentially lower risk in terms of short-term price fluctuations for A.
A vs XGN Comparison
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 32.8B. In comparison, XGN has a market cap of 158M. Regarding current trading prices, A is priced at $115.55, while XGN trades at $7.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 28.46, whereas XGN's P/E ratio is -8.61. In terms of profitability, A's ROE is +0.19%, compared to XGN's ROE of -1.34%. Regarding short-term risk, A is less volatile compared to XGN. This indicates potentially lower risk in terms of short-term price fluctuations for A.
A vs ACRS Comparison
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 32.8B. In comparison, ACRS has a market cap of 157M. Regarding current trading prices, A is priced at $115.55, while ACRS trades at $1.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 28.46, whereas ACRS's P/E ratio is -0.91. In terms of profitability, A's ROE is +0.19%, compared to ACRS's ROE of -0.92%. Regarding short-term risk, A is less volatile compared to ACRS. This indicates potentially lower risk in terms of short-term price fluctuations for A.
A vs ATLN Comparison
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 32.8B. In comparison, ATLN has a market cap of 143M. Regarding current trading prices, A is priced at $115.55, while ATLN trades at $2.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 28.46, whereas ATLN's P/E ratio is -0.66. In terms of profitability, A's ROE is +0.19%, compared to ATLN's ROE of -19.68%. Regarding short-term risk, A is less volatile compared to ATLN. This indicates potentially lower risk in terms of short-term price fluctuations for A.
A vs GTH Comparison
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 32.8B. In comparison, GTH has a market cap of 127.3M. Regarding current trading prices, A is priced at $115.55, while GTH trades at $4.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 28.46, whereas GTH's P/E ratio is -1.11. In terms of profitability, A's ROE is +0.19%, compared to GTH's ROE of -1.01%. Regarding short-term risk, A is more volatile compared to GTH. This indicates potentially higher risk in terms of short-term price fluctuations for A.
A vs PRE Comparison
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 32.8B. In comparison, PRE has a market cap of 116.8M. Regarding current trading prices, A is priced at $115.55, while PRE trades at $8.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 28.46, whereas PRE's P/E ratio is -2.35. In terms of profitability, A's ROE is +0.19%, compared to PRE's ROE of -0.25%. Regarding short-term risk, A is less volatile compared to PRE. This indicates potentially lower risk in terms of short-term price fluctuations for A.
A vs GENE Comparison
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 32.8B. In comparison, GENE has a market cap of 111.2M. Regarding current trading prices, A is priced at $115.55, while GENE trades at $0.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 28.46, whereas GENE's P/E ratio is -38.25. In terms of profitability, A's ROE is +0.19%, compared to GENE's ROE of -3.62%. Regarding short-term risk, A is more volatile compared to GENE. This indicates potentially higher risk in terms of short-term price fluctuations for A.
A vs MDXH Comparison
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 32.8B. In comparison, MDXH has a market cap of 98.2M. Regarding current trading prices, A is priced at $115.55, while MDXH trades at $1.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 28.46, whereas MDXH's P/E ratio is -1.91. In terms of profitability, A's ROE is +0.19%, compared to MDXH's ROE of -6.91%. Regarding short-term risk, A is less volatile compared to MDXH. This indicates potentially lower risk in terms of short-term price fluctuations for A.
A vs VNRX Comparison
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 32.8B. In comparison, VNRX has a market cap of 83.2M. Regarding current trading prices, A is priced at $115.55, while VNRX trades at $0.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 28.46, whereas VNRX's P/E ratio is -2.99. In terms of profitability, A's ROE is +0.19%, compared to VNRX's ROE of +1.08%. Regarding short-term risk, A is less volatile compared to VNRX. This indicates potentially lower risk in terms of short-term price fluctuations for A.
A vs SERA Comparison
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 32.8B. In comparison, SERA has a market cap of 70.5M. Regarding current trading prices, A is priced at $115.55, while SERA trades at $1.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 28.46, whereas SERA's P/E ratio is -2.04. In terms of profitability, A's ROE is +0.19%, compared to SERA's ROE of -0.51%. Regarding short-term risk, A is less volatile compared to SERA. This indicates potentially lower risk in terms of short-term price fluctuations for A.
A vs NOTV Comparison
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 32.8B. In comparison, NOTV has a market cap of 70.4M. Regarding current trading prices, A is priced at $115.55, while NOTV trades at $2.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 28.46, whereas NOTV's P/E ratio is -0.66. In terms of profitability, A's ROE is +0.19%, compared to NOTV's ROE of -0.51%. Regarding short-term risk, A is less volatile compared to NOTV. This indicates potentially lower risk in terms of short-term price fluctuations for A.
A vs OPGN Comparison
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 32.8B. In comparison, OPGN has a market cap of 48.4M. Regarding current trading prices, A is priced at $115.55, while OPGN trades at $4.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 28.46, whereas OPGN's P/E ratio is -0.31. In terms of profitability, A's ROE is +0.19%, compared to OPGN's ROE of +1.20%. Regarding short-term risk, A is more volatile compared to OPGN. This indicates potentially higher risk in terms of short-term price fluctuations for A.
A vs BDSX Comparison
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 32.8B. In comparison, BDSX has a market cap of 38.4M. Regarding current trading prices, A is priced at $115.55, while BDSX trades at $0.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 28.46, whereas BDSX's P/E ratio is -0.97. In terms of profitability, A's ROE is +0.19%, compared to BDSX's ROE of -1.68%. Regarding short-term risk, A is less volatile compared to BDSX. This indicates potentially lower risk in terms of short-term price fluctuations for A.
A vs DRIO Comparison
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 32.8B. In comparison, DRIO has a market cap of 30.7M. Regarding current trading prices, A is priced at $115.55, while DRIO trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 28.46, whereas DRIO's P/E ratio is -1.25. In terms of profitability, A's ROE is +0.19%, compared to DRIO's ROE of -0.17%. Regarding short-term risk, A is less volatile compared to DRIO. This indicates potentially lower risk in terms of short-term price fluctuations for A.
A vs STRRP Comparison
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 32.8B. In comparison, STRRP has a market cap of 28.7M. Regarding current trading prices, A is priced at $115.55, while STRRP trades at $8.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 28.46, whereas STRRP's P/E ratio is -4.48. In terms of profitability, A's ROE is +0.19%, compared to STRRP's ROE of -0.24%. Regarding short-term risk, A is more volatile compared to STRRP. This indicates potentially higher risk in terms of short-term price fluctuations for A.
A vs AKU Comparison
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 32.8B. In comparison, AKU has a market cap of 26.3M. Regarding current trading prices, A is priced at $115.55, while AKU trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 28.46, whereas AKU's P/E ratio is -0.13. In terms of profitability, A's ROE is +0.19%, compared to AKU's ROE of -5.32%. Regarding short-term risk, A is less volatile compared to AKU. This indicates potentially lower risk in terms of short-term price fluctuations for A.
A vs PRPO Comparison
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 32.8B. In comparison, PRPO has a market cap of 17.3M. Regarding current trading prices, A is priced at $115.55, while PRPO trades at $11.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 28.46, whereas PRPO's P/E ratio is -5.57. In terms of profitability, A's ROE is +0.19%, compared to PRPO's ROE of -0.26%. Regarding short-term risk, A is less volatile compared to PRPO. This indicates potentially lower risk in terms of short-term price fluctuations for A.
A vs CEMI Comparison
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 32.8B. In comparison, CEMI has a market cap of 16.7M. Regarding current trading prices, A is priced at $115.55, while CEMI trades at $0.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 28.46, whereas CEMI's P/E ratio is -0.63. In terms of profitability, A's ROE is +0.19%, compared to CEMI's ROE of -0.89%. Regarding short-term risk, A is more volatile compared to CEMI. This indicates potentially higher risk in terms of short-term price fluctuations for A.
A vs ENZ Comparison
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 32.8B. In comparison, ENZ has a market cap of 16.4M. Regarding current trading prices, A is priced at $115.55, while ENZ trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 28.46, whereas ENZ's P/E ratio is -2.24. In terms of profitability, A's ROE is +0.19%, compared to ENZ's ROE of -0.39%. Regarding short-term risk, A is less volatile compared to ENZ. This indicates potentially lower risk in terms of short-term price fluctuations for A.
A vs PMD Comparison
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 32.8B. In comparison, PMD has a market cap of 15.7M. Regarding current trading prices, A is priced at $115.55, while PMD trades at $2.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 28.46, whereas PMD's P/E ratio is -5.24. In terms of profitability, A's ROE is +0.19%, compared to PMD's ROE of -0.33%. Regarding short-term risk, A is less volatile compared to PMD. This indicates potentially lower risk in terms of short-term price fluctuations for A.
A vs ADVB Comparison
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 32.8B. In comparison, ADVB has a market cap of 15M. Regarding current trading prices, A is priced at $115.55, while ADVB trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 28.46, whereas ADVB's P/E ratio is -4.33. In terms of profitability, A's ROE is +0.19%, compared to ADVB's ROE of -1.86%. Regarding short-term risk, A is less volatile compared to ADVB. This indicates potentially lower risk in terms of short-term price fluctuations for A.
A vs ME Comparison
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 32.8B. In comparison, ME has a market cap of 13.3M. Regarding current trading prices, A is priced at $115.55, while ME trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 28.46, whereas ME's P/E ratio is -0.03. In terms of profitability, A's ROE is +0.19%, compared to ME's ROE of -3.10%. Regarding short-term risk, A is less volatile compared to ME. This indicates potentially lower risk in terms of short-term price fluctuations for A.
A vs INBS Comparison
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 32.8B. In comparison, INBS has a market cap of 12.3M. Regarding current trading prices, A is priced at $115.55, while INBS trades at $1.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 28.46, whereas INBS's P/E ratio is -1.34. In terms of profitability, A's ROE is +0.19%, compared to INBS's ROE of -1.72%. Regarding short-term risk, A is less volatile compared to INBS. This indicates potentially lower risk in terms of short-term price fluctuations for A.
A vs BNGO Comparison
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 32.8B. In comparison, BNGO has a market cap of 10.8M. Regarding current trading prices, A is priced at $115.55, while BNGO trades at $3.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 28.46, whereas BNGO's P/E ratio is -0.06. In terms of profitability, A's ROE is +0.19%, compared to BNGO's ROE of -1.57%. Regarding short-term risk, A is less volatile compared to BNGO. This indicates potentially lower risk in terms of short-term price fluctuations for A.
A vs TRIB Comparison
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 32.8B. In comparison, TRIB has a market cap of 10.7M. Regarding current trading prices, A is priced at $115.55, while TRIB trades at $0.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 28.46, whereas TRIB's P/E ratio is -0.32. In terms of profitability, A's ROE is +0.19%, compared to TRIB's ROE of +0.79%. Regarding short-term risk, A is less volatile compared to TRIB. This indicates potentially lower risk in terms of short-term price fluctuations for A.
A vs CNTG Comparison
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 32.8B. In comparison, CNTG has a market cap of 9.4M. Regarding current trading prices, A is priced at $115.55, while CNTG trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 28.46, whereas CNTG's P/E ratio is -0.23. In terms of profitability, A's ROE is +0.19%, compared to CNTG's ROE of +3.98%. Regarding short-term risk, A is less volatile compared to CNTG. This indicates potentially lower risk in terms of short-term price fluctuations for A.
A vs BIAFW Comparison
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 32.8B. In comparison, BIAFW has a market cap of 7.5M. Regarding current trading prices, A is priced at $115.55, while BIAFW trades at $0.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 28.46, whereas BIAFW's P/E ratio is N/A. In terms of profitability, A's ROE is +0.19%, compared to BIAFW's ROE of -3.68%. Regarding short-term risk, A is more volatile compared to BIAFW. This indicates potentially higher risk in terms of short-term price fluctuations for A.
A vs BIAF Comparison
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 32.8B. In comparison, BIAF has a market cap of 6.7M. Regarding current trading prices, A is priced at $115.55, while BIAF trades at $0.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 28.46, whereas BIAF's P/E ratio is -0.33. In terms of profitability, A's ROE is +0.19%, compared to BIAF's ROE of -3.68%. Regarding short-term risk, A is less volatile compared to BIAF. This indicates potentially lower risk in terms of short-term price fluctuations for A.
A vs STRR Comparison
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 32.8B. In comparison, STRR has a market cap of 6.5M. Regarding current trading prices, A is priced at $115.55, while STRR trades at $2.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 28.46, whereas STRR's P/E ratio is -0.67. In terms of profitability, A's ROE is +0.19%, compared to STRR's ROE of -0.24%. Regarding short-term risk, A is less volatile compared to STRR. This indicates potentially lower risk in terms of short-term price fluctuations for A.
A vs MYNZ Comparison
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 32.8B. In comparison, MYNZ has a market cap of 5.5M. Regarding current trading prices, A is priced at $115.55, while MYNZ trades at $1.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 28.46, whereas MYNZ's P/E ratio is -0.06. In terms of profitability, A's ROE is +0.19%, compared to MYNZ's ROE of -22.70%. Regarding short-term risk, A is less volatile compared to MYNZ. This indicates potentially lower risk in terms of short-term price fluctuations for A.
A vs NVTA Comparison
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 32.8B. In comparison, NVTA has a market cap of 5.4M. Regarding current trading prices, A is priced at $115.55, while NVTA trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 28.46, whereas NVTA's P/E ratio is -0.00. In terms of profitability, A's ROE is +0.19%, compared to NVTA's ROE of -2.02%. Regarding short-term risk, A is less volatile compared to NVTA. This indicates potentially lower risk in terms of short-term price fluctuations for A.
A vs BGLC Comparison
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 32.8B. In comparison, BGLC has a market cap of 5.2M. Regarding current trading prices, A is priced at $115.55, while BGLC trades at $2.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 28.46, whereas BGLC's P/E ratio is -2.41. In terms of profitability, A's ROE is +0.19%, compared to BGLC's ROE of -0.24%. Regarding short-term risk, A is less volatile compared to BGLC. This indicates potentially lower risk in terms of short-term price fluctuations for A.
A vs LMDX Comparison
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 32.8B. In comparison, LMDX has a market cap of 5.1M. Regarding current trading prices, A is priced at $115.55, while LMDX trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 28.46, whereas LMDX's P/E ratio is -0.01. In terms of profitability, A's ROE is +0.19%, compared to LMDX's ROE of -15.58%. Regarding short-term risk, A is less volatile compared to LMDX. This indicates potentially lower risk in terms of short-term price fluctuations for A.
A vs LMDXW Comparison
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 32.8B. In comparison, LMDXW has a market cap of 5.1M. Regarding current trading prices, A is priced at $115.55, while LMDXW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 28.46, whereas LMDXW's P/E ratio is N/A. In terms of profitability, A's ROE is +0.19%, compared to LMDXW's ROE of -15.58%. Regarding short-term risk, A is less volatile compared to LMDXW. This indicates potentially lower risk in terms of short-term price fluctuations for A.
A vs CHEK Comparison
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 32.8B. In comparison, CHEK has a market cap of 4.3M. Regarding current trading prices, A is priced at $115.55, while CHEK trades at $0.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 28.46, whereas CHEK's P/E ratio is -0.35. In terms of profitability, A's ROE is +0.19%, compared to CHEK's ROE of -0.52%. Regarding short-term risk, A is less volatile compared to CHEK. This indicates potentially lower risk in terms of short-term price fluctuations for A.
A vs TTOO Comparison
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 32.8B. In comparison, TTOO has a market cap of 4M. Regarding current trading prices, A is priced at $115.55, while TTOO trades at $0.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 28.46, whereas TTOO's P/E ratio is -4.76. In terms of profitability, A's ROE is +0.19%, compared to TTOO's ROE of +2.06%. Regarding short-term risk, A is less volatile compared to TTOO. This indicates potentially lower risk in terms of short-term price fluctuations for A.
A vs BNR Comparison
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 32.8B. In comparison, BNR has a market cap of 3.9M. Regarding current trading prices, A is priced at $115.55, while BNR trades at $3.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 28.46, whereas BNR's P/E ratio is -1.12. In terms of profitability, A's ROE is +0.19%, compared to BNR's ROE of -0.53%. Regarding short-term risk, A is less volatile compared to BNR. This indicates potentially lower risk in terms of short-term price fluctuations for A.
A vs DMTK Comparison
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 32.8B. In comparison, DMTK has a market cap of 3.3M. Regarding current trading prices, A is priced at $115.55, while DMTK trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 28.46, whereas DMTK's P/E ratio is -0.04. In terms of profitability, A's ROE is +0.19%, compared to DMTK's ROE of -0.80%. Regarding short-term risk, A is less volatile compared to DMTK. This indicates potentially lower risk in terms of short-term price fluctuations for A.
A vs AWH Comparison
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 32.8B. In comparison, AWH has a market cap of 2.9M. Regarding current trading prices, A is priced at $115.55, while AWH trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 28.46, whereas AWH's P/E ratio is -0.09. In terms of profitability, A's ROE is +0.19%, compared to AWH's ROE of +4.66%. Regarding short-term risk, A is less volatile compared to AWH. This indicates potentially lower risk in terms of short-term price fluctuations for A.
A vs APDN Comparison
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 32.8B. In comparison, APDN has a market cap of 2.7M. Regarding current trading prices, A is priced at $115.55, while APDN trades at $5.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 28.46, whereas APDN's P/E ratio is N/A. In terms of profitability, A's ROE is +0.19%, compared to APDN's ROE of -2.81%. Regarding short-term risk, A is less volatile compared to APDN. This indicates potentially lower risk in terms of short-term price fluctuations for A.
A vs SQL Comparison
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 32.8B. In comparison, SQL has a market cap of 2.5M. Regarding current trading prices, A is priced at $115.55, while SQL trades at $6.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 28.46, whereas SQL's P/E ratio is -0.40. In terms of profitability, A's ROE is +0.19%, compared to SQL's ROE of +10.89%. Regarding short-term risk, A is less volatile compared to SQL. This indicates potentially lower risk in terms of short-term price fluctuations for A.
A vs ISPC Comparison
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 32.8B. In comparison, ISPC has a market cap of 2.4M. Regarding current trading prices, A is priced at $115.55, while ISPC trades at $0.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 28.46, whereas ISPC's P/E ratio is -0.08. In terms of profitability, A's ROE is +0.19%, compared to ISPC's ROE of -2.39%. Regarding short-term risk, A is less volatile compared to ISPC. This indicates potentially lower risk in terms of short-term price fluctuations for A.
A vs NDRA Comparison
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 32.8B. In comparison, NDRA has a market cap of 2.3M. Regarding current trading prices, A is priced at $115.55, while NDRA trades at $3.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 28.46, whereas NDRA's P/E ratio is 0.01. In terms of profitability, A's ROE is +0.19%, compared to NDRA's ROE of -1.96%. Regarding short-term risk, A is less volatile compared to NDRA. This indicates potentially lower risk in terms of short-term price fluctuations for A.
A vs HTGM Comparison
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 32.8B. In comparison, HTGM has a market cap of 1.1M. Regarding current trading prices, A is priced at $115.55, while HTGM trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 28.46, whereas HTGM's P/E ratio is -0.03. In terms of profitability, A's ROE is +0.19%, compared to HTGM's ROE of -2.73%. Regarding short-term risk, A is more volatile compared to HTGM. This indicates potentially higher risk in terms of short-term price fluctuations for A.
A vs SQLLW Comparison
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 32.8B. In comparison, SQLLW has a market cap of 482K. Regarding current trading prices, A is priced at $115.55, while SQLLW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 28.46, whereas SQLLW's P/E ratio is -0.02. In terms of profitability, A's ROE is +0.19%, compared to SQLLW's ROE of -19.68%. Regarding short-term risk, A is more volatile compared to SQLLW. This indicates potentially higher risk in terms of short-term price fluctuations for A.
A vs BIOC Comparison
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 32.8B. In comparison, BIOC has a market cap of 450.8K. Regarding current trading prices, A is priced at $115.55, while BIOC trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 28.46, whereas BIOC's P/E ratio is -0.01. In terms of profitability, A's ROE is +0.19%, compared to BIOC's ROE of -1.38%. Regarding short-term risk, A is less volatile compared to BIOC. This indicates potentially lower risk in terms of short-term price fluctuations for A.
A vs DHR-PA Comparison
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 32.8B. In comparison, DHR-PA has a market cap of 0. Regarding current trading prices, A is priced at $115.55, while DHR-PA trades at $1,841.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 28.46, whereas DHR-PA's P/E ratio is 233.57. In terms of profitability, A's ROE is +0.19%, compared to DHR-PA's ROE of +0.07%. Regarding short-term risk, A is less volatile compared to DHR-PA. This indicates potentially lower risk in terms of short-term price fluctuations for A.
A vs OCDX Comparison
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 32.8B. In comparison, OCDX has a market cap of 0. Regarding current trading prices, A is priced at $115.55, while OCDX trades at $17.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 28.46, whereas OCDX's P/E ratio is -42.28. In terms of profitability, A's ROE is +0.19%, compared to OCDX's ROE of +0.18%. Regarding short-term risk, A is less volatile compared to OCDX. This indicates potentially lower risk in terms of short-term price fluctuations for A.
A vs MEUSW Comparison
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 32.8B. In comparison, MEUSW has a market cap of 0. Regarding current trading prices, A is priced at $115.55, while MEUSW trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 28.46, whereas MEUSW's P/E ratio is N/A. In terms of profitability, A's ROE is +0.19%, compared to MEUSW's ROE of -3.10%. Regarding short-term risk, A is less volatile compared to MEUSW. This indicates potentially lower risk in terms of short-term price fluctuations for A.